Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-Mediated apoptosis

Neoplasia

Volumn 13, Issue 3, 2011, Pages 198-205

  Watson, Gregory A ^a   Naran, Sanjay ^a   Zhang, Xinglu ^a   Stang, Michael T ^a   de Oliveira, Pierre E Queiroz ^a   Hughes, Steven J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; FAS ANTIGEN; FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RNA;

APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL CULTURE; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME INHIBITION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TRANSPORT; SECRETORY VESICLE; SQUAMOUS CELL; TUMOR RESISTANCE;

EID: 79952398111     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101304     Document Type: Article

References (36)

1. Ehrenschwender M and Wajant H (2009). The role of FasL and fas in health and disease. Adv Exp Med Biol 647, 64-93.
2. Guicciardi ME and Gores GJ (2009). Life and death by death receptors. FASEB J 23, 1625-1637.
3. Lee KH, Feig C, Tchikov V, Schickel R, Hallas C, Schutze S, Peter ME, and Chan AC (2006). The role of receptor internalization in CD95 signaling. EMBO J 25, 1009-1023.
4. Owen-Schaub L, Chan H, Cusack JC, Roth J, and Hill LL (2000). Fas and Fas ligand interactions in malignant disease. Int J Oncol 17, 5-12.
5. O'Brien DI, Nally K, Kelly RG, O'Connor TM, Shanahan F, and O'Connell J (2005). Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets 9, 1031-1044.
6. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, et al. (2007). The CD95 receptor: apoptosis revisited. Cell 129, 447-450.
7. Wajant H, Pfizenmaier K, and Scheurich P (2003). Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 14, 53-66.
8. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, et al. (2010). CD95 promotes tumour growth. Nature 465, 492-496.
9. Ferguson TA and Griffith TS (2006). A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev 213, 228-238.
10. Filippini A, Riccioli A, Padula F, Lauretti P, D'Alessio A, De Cesaris P, Gandini L, Lenzi A, and Ziparo E (2001). Control and impairment of immune privilege in the testis and in semen. Hum Reprod Update 7, 444-449.
11. Guller S and LaChapelle L (1999). The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces. Semin Reprod Endocrinol 17, 39-44.
12. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, et al. (1996). Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366.
13. O'Connell J, O'Sullivan GC, Collins JK, and Shanahan F (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184, 1075-1082.
14. Whiteside TL (2007). The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 36, 25-46.
15. Kozlowski M, Kowalczuk O, Sulewska A, Dziegielewski P, Lapuc G, Laudanski W, Niklinska W, Chyczewski L, Niklinski J, and Laudanski J (2007). Serum soluble Fas ligand (sfasL) in patients with primary squamous cell carcinoma of the esophagus. Folia Histochem Cytobiol 45, 199-204.
16. Houston AM, Michael-Robinson JM, Walsh MD, Cummings MC, Ryan AE, Lincoln D, Pandeya N, Jass JR, Radford-Smith GL, and O'Connell J (2008). The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. Hum Pathol 39, 243-250.
17. Ryan AE, Shanahan F, O'Connell J, and Houston AM (2005). Addressing the "Fas counterattack" controversy: blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 65, 9817-9823.
18. O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT, et al. (2009). Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461, 659-663.
19. Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB, and Beer DG (1997). Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 57, 5571-5578.
20. Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, and Beer DG (1998). Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 101, 1102-1110.
21. Haefner B (2006). Targeting NF-κB in anticancer adjunctive chemotherapy. Cancer Treat Res 130, 219-245.
22. Jaiswal KR, Morales CP, Feagins LA, Gandia KG, Zhang X, Zhang HY, Hormi-Carver K, Shen Y, Elder F, Ramirez RD, et al. (2007). Characterization of telomerase-immortalized, non-neoplastic, human Barrett's cell line (BAR-T). Dis Esophagus 20, 256-264.
23. Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, and Sarkar FH (2006). Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 106, 1260-1268.
24. Sandur SK, Ichikawa H, Sethi G, Ahn KS, and Aggarwal BB (2006). Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-κB activation and NF-κB-regulated gene products through modulation of p65 and I?Ba kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 281, 17023-17033.
25. Kase S, Osaki M, Adachi H, Kaibara N, and Ito H (2002). Expression of Fas and fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol 20, 291-297.
26. Ding EX, Hizuta A, Morimoto Y, Tanida T, Hongo T, Ishii T, Yamano T, Fujiwara T, Iwagaki H, and Tanaka N (1998). Human colon cancer cells express the functional Fas ligand. Res Commun Mol Pathol Pharmacol 101, 13-24.
27. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, and Kratzke RA (1997). Human lung carcinomas express Fas ligand. Cancer Res 57, 1007-1012.
28. Curtin JF and Cotter TG (2003). Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 15, 983-992.
29. Kavurma MM and Khachigian LM (2003). Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 10, 36-44.
30. Bergmann C, Strauss L, Wieckowski E, Czystowska M, Albers A, Wang Y, Zeidler R, Lang S, and Whiteside TL (2009). Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 31, 371-380.
31. Peter ME, Dhein J, Ehret A, Hellbardt S, Walczak H, Moldenhauer G, and Krammer PH (1995). APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human Tand B cell lines. Int Immunol 7, 1873-1877.
32. Stang MT, Armstrong MJ, Watson GA, Sung KY, Liu Y, Ren B, and Yim JH (2007). Interferon regulatory factor-1-induced apoptosis mediated by a ligandindependent Fas-associated death domain pathway in breast cancer cells. Oncogene 26, 6420-6430.
33. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, and Shanahan F (1998). The Fas counterattack in vivo: apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160, 5669-5675.
34. Desbarats J and Newell MK (2000). Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 6, 920-923.
35. Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, and Newell MK (2003). Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 5, 118-125.
36. Lancaster GI and Febbraio MA (2005). Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem 280, 23349-23355.